TrianglePembrolizumab (NCT06731907)
Pembrolizumab trial for Non-small Cell Lung Cancer (NCT06731907). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with stage IV squamous or nonsquamous non-small-cell lung cancer, without previous systemic treatment for metastatic disease or checkpoint immunotherapy. Additional mutation and fitness criteria apply.
The idea: compare pembrolizumab plus platinum chemotherapy against pembrolizumab plus patritumab deruxtecan. Pembrolizumab blocks PD-1; patritumab deruxtecan targets HER3 to deliver a payload that disrupts DNA copying. These are separate treatment groups. Researchers assess tumor response and side effects. Treatment uses three-week cycles, with chemotherapy schedules differing by cancer type.
This phase 2 study plans 90 patients. Merck sponsors five recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.